Microwave-enhanced medicinal chemistry: A high-speed opportunity for convenient preparation of protease inhibitors

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 4, 2004, Pages 417-427

  Ersmark, Karolina ^a   Larhed, Mats ^a   Wannberg, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

High speed chemistry; HIV 1 protease inhibitor; Microwave; Palladium catalysis; Plasmepsin I inhibitor; Plasmepsin II inhibitor

Indexed keywords

ASPARTIC PROTEINASE; PALLADIUM; PLASMEPSIN I; PLASMEPSIN II; PROTEINASE INHIBITOR; VIRUS PROTEIN; PLASMEPSIN;

CATALYSIS; CLINICAL CHEMISTRY; DRUG RESEARCH; DRUG SYNTHESIS; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; MALARIA; MICROWAVE COOKING; MICROWAVE RADIATION; REVIEW; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; HEAT; METHODOLOGY; SYNTHESIS; TIME;

ASPARTIC ENDOPEPTIDASES; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; HEAT; HIV PROTEASE INHIBITORS; MICROWAVES; PROTEASE INHIBITORS; TIME FACTORS;

EID: 4644273521     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Larhed M, Hallberg A: Microwave-assisted high-speed chemistry: A new technique in drug discovery. Drug Disc Today (2001) 6(8):406-416.
2. Lew A, Krutzik PO, Hart ME, Chamberlin AR: Increasing rates of reaction: Microwave-assisted organic synthesis for combinatorial chemistry. J Comb Chem (2002) 4(2):95-105. A comprehensive review of the use of microwave heating in combinatorial chemistry.
3. Hunter D: Life in the fast lane: High-throughput chemistry for lead generation and optimisation. J Cell Biochem Suppl (2001) (Suppl 37):22-27.
4. Curran DP: Strategy-level separations in organic synthesis: From planning to practice. Angew Chem Int Ed (1998) 37:1175-1196.
5. Curran DP: Fluorous reverse phase silica gel. A new tool for preparative separations in synthetic organic and organofluorine chemistry. Synlett (2001) 9:1488-1496.
6. Ley SV, Baxendale IR: New tools and concepts for modern organic synthesis. Nat Rev Drug Disc (2002) 1(8):573-586.
7. Strauss CR, Trainor RW: Developments in microwave-assisted organic chemistry. Aust J Chem (1995) 48:1665-1692. A fundamental overview by the true pioneers in the field of microwave-assisted organic chemistry.
8. Lidström P, Tierney J, Wathey B, Westman J: Microwave assisted organic synthesis: A review. Tetrahedron (2001) 57:9225-9283. Currently the most comprehensive review available on microwave-enhanced organic chemistry.
9. Kappe CO: High-speed combinatorial synthesis utilizing microwave irradiation. Curr Opin Chem Biol (2002) 6(3):314-320.
10. Larhed M, Moberg C, Hallberg A: Microwave-accelerated homogeneous catalysis in organic chemistry. Acc Chem Res (2002) 35(9):717-727.
11. Loupy A (Ed): Microwaves in Organic Synthesis. Wiley-VCH, Weinheim, Germany (2002).
12. Elander N, Jones JR, Lu S-Y, Stone-Elander S: Microwave-enhanced radiochemistry. Chem Soc Rev (2000) 29:239-249.
13. Stadler A, Yousefi BH, Dallinger D, Walla P, Van der Eycken E, Kaval N, Kappe CO: Scalability of microwave-assisted organic synthesis. From single-mode to multimode parallel batch reactors. Org Process Res Dev (2003) 7(5):707-716.
14. Suzuki A: Cross-coupling reactions via organoboranes. J Organomet Chem (2002) 653(1-2):83-90.
15. Farina V, Krishnamurthy V, Scott WJ: The Stille reaction. Org React (1997) 50:1-652.
16. Negishi E-I: Overview of the Negishi protocol with Zn, Al, Zr and related metals. In: Handbook of Organopalladium Chemistry for Organic Synthesis. Negishi E-I (Ed), Wiley-Interscience, New York, NY, USA (2002):229-248.
17. Larhed M, Hallberg A: The Heck reaction (alkene substitution via carbopalladation-dehydropalladation) and related carbopalladation reactions. In: Handbook of Organopalladium Chemistry for Organic Synthesis. Negishi E-I (Ed), Wiley-Interscience, New York, NY, USA (2002):1133-1178.
18. Sonogashira K: Sonogashira alkyne synthesis. In: Handbook of Organopalladium Chemistry for Organic Synthesis. Negishi E-I (Ed), Wiley-Interscience, New York, NY, USA (2002):493-529.
19. Takagi K: Palladium-catalyzed cross-coupling involving metal cyanides. In: Handbook of Organopalladium Chemistry for Organic Synthesis. Negishi E-I (Ed), Wiley-Interscience, New York, NY, USA (2002):657-672.
20. Mori M: Palladium-catalyzed carbonylation of aryl and vinylic halides. In: Handbook of Organopalladium Chemistry for Organic Synthesis. Negishi E (Ed), Wiley-Interscience, New York, NY, USA (2002):2313-2332.
21. Schechter I, Berger A: On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 27(2):157-162.
22. Bremen JG: The ears of the Hippopotamus: Manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg (2001) 64(1-2 Suppl):1-11.
23. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT et al: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 419(6906):498-511. An analysis of the complete P falciparum genome sequence.
24. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE: Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA (2002) 99(2):990-995.
25. Berry C: Plasmepsins as antimalarial targets. Curr Opin Drug Discovery Dev (2000) 3(5):624-629.
26. Boss C, Richard-Bildstein S, Weller T, Fischli W, Meyer S, Binkert C: Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem (2003) 10(11):883-907.
27. Silva AM, Lee AY, Gulnik SV, Maier P, Collins J, Bhat TN, Collins PJ, Cachau RE, Luker KE, Gluzman IY, Francis SE et al: Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci USA (1996) 93(19):10034-10039. The first and most extensively studied crystal structure of Plm II.
28. Haque TS, Skillman AG, Lee CE, Habashita H, Gluzman IY, Ewing TJ, Goldberg DE, Kuntz ID, Ellman JA: Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J Med Chem (1999) 42(8):1428-1440.
29. Carroll CD, Patel H, Johnson TO, Guo T, Orlowski M, He ZM, Cavallaro CL, Guo J, Oksman A, Gluzman IY, Connelly J et al: Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett (1998) 8(17):2315-2320.
30. Nöteberg D, Hamelink E, Hultén J, Wahlgren M, Vrang L, Samuelsson B, Hallberg A: Design and synthesis of plasmepsin I and plasmepsin II Inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. J Med Chem (2003) 46(5):734-746.
31. Nöteberg D, Schaal W, Hamelink E, Vrang L, Larhed M: High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II. J Comb Chem (2003) 5(4):456-464.
32. 2-Symmetric inhibitors of Plasmodium falciparum plasmepsin II: Synthesis and theoretical predictions. Bioorg Med Chem (2003) 11(17):3723-3733.
33. Ersmark K, Feierberg I, Bjelic S, Hamelink E, Hackett F, Blackman MJ, Hulten J, Samuelsson B, Qvist J, Hallberg A: Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J Med Chem (2003) 47(1):110-122.
34. Centers for Disease Control: Pneumocystis pneumonia - Los Angeles. Morb Mortal Wkly Rep (1981) 30(21):250-252.
35. Centers for Disease Control: Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. Morb Mortal Wkly Rep (1981) 30(25):305-308.
36. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W et al: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220(4599):868-871.
37. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K et al: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 313(6000):277-284.
38. Pearl LH, Taylor WR: A structural model for the retroviral proteases. Nature (1987) 329(6137):351-354.
39. Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL, Springer JP: Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 337(6208):615-620. The first published crystal structure of HIV protease.
40. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA (1988) 85(13):4686-4690. Validation of the HIV protease as a target for drug discovery.
41. Huff JR, Kahn J: Discovery and clinical development of HIV-1 protease inhibitors. Adv Protein Chem (2001) 56:213-251.
42. Brik A, Wong CH: HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem (2003) 1(1):5-14. A recent review discussing the mechanism and inhibition of HIV-1 protease.
43. Mocroft A, Vella S, Benfield TL, Chiesi A. Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD: Changing patterns of mortality across Europe in patients Infected with HIV-1. Lancet (1998) 352(9142):1725-1730.
44. Jacobson MA, French M: Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS (1998) 12(Suppl A):S157-S163.
45. 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J Med Chem (1998) 41(20):3782-3792.
46. 2-symmetric P1/P1′-modified HIV-1 protease inhibitors. J Med Chem (1999) 42(19):3835-3844.
47. Alterman M, Hallberg A: Fast microwave-assisted preparation of aryl and vinyl nitrites and the corresponding tetrazoles from organohalides. J Org Chem (2000) 65(23):7984-7989.
48. Hulten J, Bonham NM, Nillroth U, Hansson T, Zuccarello G, Bouzide A, Aqvist J, Classon B, Danielson UH, Karlen A, Kvarnstrom I et al: Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities. J Med Chem (1997) 40(6):885-897.
49. 2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2′ side chains. J Med Chem (1999) 42(20):4054-4061.
50. Cramer RD, Patterson DE, Bunce JD: Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 110:5959-5967.
51. Schaal W, Kartsson A, Ahlsen G, Lindberg J, Andersson HO, Danielson UH, Classon B, Unge T, Samuelsson B, Hulten J, Hallberg A et al: Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J Med Chem (2001) 44(2):155-169.